Relationship between myalgias/arthralgias occuring in patients receiving quinupristin/dalfopristin and biliary dysfunction

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 6, 2004, Pages 1105-1108

  Raad, Issam ^a   Hachem, Ray ^a   Hanna, Hend ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alkaline phosphatase; Vancomycin resistant enterococci; VRE

Indexed keywords

ALKALINE PHOSPHATASE; DALFOPRISTIN PLUS QUINUPRISTIN; METHOTREXATE; MINOCYCLINE; TACROLIMUS; VANCOMYCIN;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ENTEROCOCCUS; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HEPATOBILIARY DISEASE; HUMAN; INTRAHEPATIC CHOLESTASIS; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; MYALGIA; OBSTRUCTIVE JAUNDICE; STATISTICAL ANALYSIS;

AGED; ALKALINE PHOSPHATASE; ANTI-BACTERIAL AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ARTHRALGIA; BILIARY TRACT DISEASES; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FUNCTION TESTS; MALE; METHOTREXATE; MIDDLE AGED; MUSCULAR DISEASES; NEOPLASMS; PAIN; RECURRENCE; RISK FACTORS; TACROLIMUS; VIRGINIAMYCIN;

EID: 3042647786     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh234     Document Type: Article

References (10)

1. Linden, P. K., Moellering, R. C., Wood, C. A. et al. (2001). Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clinical Infectious Diseases 33, 1816-23.
2. Moellering, R. C., Linden, P. K., Reinhardt, J. et al. (1999). The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Journal of Antimicrobial Chemotherapy 44, 251-61.
3. Winston, D. J., Emmanouilides, C., Kroeber, A. et al. (2000). Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clinical Infectious Diseases 30, 790-7.
4. Olsen, K. M., Rebuck, J. A. & Rupp, M. E. (2001). Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clinical Infectious Diseases 32, e83-e86.
5. Carver, P. L., Whang, E., VandenBussche, H. L. et al. (2003). Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy. Pharmacotherapy 23, 159-64.
6. Raad, I., Hachem, R., Hanna, H. et al. (2001). Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrobial Agents and Chemotherapy 45, 3202-4.
7. Talbot, G. H. & Zhu, G. R. (1998). Characterization of arthralgias/myalgias associated with quinupristin/dalfopristin (Synercid). Clinical Infectious Diseases 27, 965.
8. Bergeron, M. & Montay, G. (1997). The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 129-38.
9. Anonymous. (2003). Tacrolimus: adverse reactions. In Physicians' Desk Reference, 5th edn, p. 1375. Thomson PDR, Montvale, NJ, USA.
10. Anonymous. (2003). Methotrexate: adverse reactions. In Physicians' Desk Reference, 5th edn, p. 3418. Thomson PDR, Montvale, NJ, USA.